Discovery and Preclinical Characterization of Benzofuran Derivatives as Potent, Selective, and Orally Bioavailable GSPT1 Molecular Glue Degraders for the Treatment of MYC-Driven Cancers

Abstract Targeted protein degradation of the translation termination factor GSPT1 is a promising cancer strategy. However, current cereblon-recruiting molecular glue degraders (MGDs) lack structural diversity, being mostly IMiD derivatives. To overcome resistance and improve drug-like properties, we report the rational, structure-guided design of a novel series of benzofuran-based GSPT1 MGDs. Extensive structure−activity relationship studies and optimization led to the discovery of highly potent, orally bioavailable degraders, highlighted by compounds C-3 and C-4. Both exhibited single-digit nanomolar GSPT1 degradation (DC50 = 2.81 and 1.91 nM) and robust selectivity over IMiD off-targets IKZF1 and SALL4. In vivo, oral administration (1−2 mg/kg) of C-3 and C-4 demonstrated favorable cross-species pharmacokinetics and achieved sustained tumor regression in NCI-H1155 and MDA-MB-468 xenograft models. With a maximum tolerated dose exceeding 100 mg/kg and no hematological toxicity, these benzofuran-based MGDs are highly promising preclinical candidates for solid tumors.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-16
DOI
https://doi.org/10.1021/acs.jmedchem.6c01738
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Discovery and Preclinical Characterization of Benzofuran Derivatives as Potent, Selective, and Orally Bioavailable GSPT1 Molecular Glue Degraders for the Treatment of MYC-Driven Cancers

Cancan Cai, Yujie Chang, Mengting Zhao, Zhimin Zhang et al.
5 links
Journal of Medicinal Chemistry
Protein Degradation and Inhibitors
article

Discovery and Preclinical Characterization of Benzofuran Derivatives as Potent, Selective, and Orally Bioavailable GSPT1 Molecular Glue Degraders for the Treatment of MYC-Driven Cancers

Cancan Cai, Yujie Chang, Mengting Zhao, Zhimin Zhang, Li Teng, Dongzhou Liu, Xiaoyan Deng, Jiangqi He, Xiaohua Zhang, Jingwen E
article en

Abstract

Abstract Targeted protein degradation of the translation termination factor GSPT1 is a promising cancer strategy. However, current cereblon-recruiting molecular glue degraders (MGDs) lack structural diversity, being mostly IMiD derivatives. To overcome resistance and improve drug-like properties, we report the rational, structure-guided design of a novel series of benzofuran-based GSPT1 MGDs. Extensive structure−activity relationship studies and optimization led to the discovery of highly potent, orally bioavailable degraders, highlighted by compounds C-3 and C-4. Both exhibited single-digit nanomolar GSPT1 degradation (DC50 = 2.81 and 1.91 nM) and robust selectivity over IMiD off-targets IKZF1 and SALL4. In vivo, oral administration (1−2 mg/kg) of C-3 and C-4 demonstrated favorable cross-species pharmacokinetics and achieved sustained tumor regression in NCI-H1155 and MDA-MB-468 xenograft models. With a maximum tolerated dose exceeding 100 mg/kg and no hematological toxicity, these benzofuran-based MGDs are highly promising preclinical candidates for solid tumors.

Journal of Medicinal Chemistry
Zhejiang Sci-Tech University (CN), Powerchina Huadong Engineering Corporation (China) (CN)
Good health and well-being
Protein Degradation and Inhibitors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon